ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy

He, Xuelei; Li, Kai; Wei, Ran; Zuo, Mengxuan; Yao, Wang; Zheng, Zechen; He, Xiaowei; Fu, Yan; Li, Chengzhi*; An, Chao*; Liu, Wendao*广东省人民医院; 西北大学; 中国医学科学院; 中山大学; 中国医学科学院北京协和医院; 1
Radiologia Medica2023-12DOI: 10.1007/s11547-023-01719-1
4被引5阅读
引用收藏
分享

摘要

Background The macrotrabecular-massive (MTM) is a special subtype of hepatocellular carcinoma (HCC), which has commonly a dismal prognosis. This study aimed to develop a multitask deep learning radiomics (MDLR) model for predicting MTM and HCC patients' prognosis after hepatic arterial infusion chemotherapy (HAIC).Methods From June 2018 to March 2020, 158 eligible patients with HCC who underwent surgery were retrospectively enrolled in MTM related cohorts, and 752 HCC patients who underwent HAIC were included in HAIC related cohorts during the same period. DLR features were extracted from dual-phase (arterial phase and venous phase) contrast-enhanced computed tomography (CECT) of the entire liver region. Then, an MDLR model was used for the simultaneous prediction of the MTM subtype and patient prognosis after HAIC. The MDLR model for prognostic risk stratification incorporated DLR signatures, clinical variables and MTM subtype.Findings The predictive performance of the DLR model for the MTM subtype was 0.968 in the training cohort [TC], 0.912 in the internal test cohort [ITC] and 0.773 in the external test cohort [ETC], respectively. Multivariable analysis identified portal vein tumor thrombus (PVTT) (p = 0.012), HAIC response (p < 0.001), HAIC sessions (p < 0.001) and MTM subtype (p < 0.001) as indicators of poor prognosis. After incorporating DLR signatures, the MDLR model yielded the best performance among all models (AUC, 0.855 in the TC, 0.805 in the ITC and 0.792 in the ETC). With these variables, the MDLR model provided two risk strata for overall survival (OS) in the TC: low risk (5-year OS, 44.9%) and high risk (5-year OS, 4.9%).Interpretation A tool based on MDLR was developed to consider that the MTM is an important prognosis factor for HCC patients. MDLR showed outstanding performance for the prognostic risk stratification of HCC patients who underwent HAIC and may help physicians with therapeutic decision making and surveillance strategy selection in clinical practice.

学科与关键词

关键词
Hepatocellular carcinomaDeep learningHepatic arterial infusion chemotherapyMacrotrabecular massivePrognostic risk stratification
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Radiologia Medica
发表日期
2023-12
卷期
第 128 卷, 第 12 期
页码
1508-1520
DOI
10.1007/s11547-023-01719-1
语言
MULTI-LANGUAGE
成果收录
SCIE
资助标注
The authors would like to acknowledge the instrumental and technical support of M.D. Xiao Li

作者

  • H

    He, Xuelei (第一作者)

    northwest univ

  • L

    Li, Kai

    sun yat sen univ

查看全部 11 位作者收起作者
  • W

    Wei, Ran

    chinese acad med sci · peking union med coll

  • Z

    Zuo, Mengxuan

    sun yat sen univ

  • Y

    Yao, Wang

    1

  • Z

    Zheng, Zechen

    guangdong prov acad chinese med sci · guangdong prov hosp

  • H

    He, Xiaowei

    guangdong prov acad chinese med sci · guangdong prov hosp

  • F

    Fu, Yan

    chinese acad med sci · peking union med coll

  • L

    Li, Chengzhi (通讯)

    sun yat sen univ

  • A

    An, Chao (通讯)

    sun yat sen univ

  • L

    Liu, Wendao (通讯)

    guangdong prov hosp · guangdong prov acad chinese med sci

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417